SYNERGY to be Boston's "premium workhorse DES" as everolimus moves to eclipse Taxus paclitaxel line
This article was originally published in Clinica
Executive Summary
The recent CE mark approval of Boston Scientific's SYNERGY resorbable drug-eluting stent marks a significant milestone in the company's strategy to strengthen its proprietary everolimus-eluting stent (EES) offering and phase out the Abbott-licensed PROMUS stent.